title: Sudden cardiac death due to β2-agonist therapy: is a genetic basis overlooked?
authors.forename: K
authors.initials: K
authors.lastname: Yalta
authors.forename: N
authors.initials: N
authors.lastname: Sivri
authors.forename: B
authors.initials: B
authors.lastname: Geyik
authors.forename: Y
authors.initials: Y
authors.lastname: Aksoy
authors.forename: E
authors.initials: E
authors.lastname: Yetkin
mesh_terms: D058666:Adrenergic beta-2 Receptor Agonists / Q000008:administration & dosage / Q000009:adverse effects*; D054316:Biomarkers, Pharmacological / Q000378:metabolism; D016757:Death, Sudden, Cardiac / Q000209:etiology* / Q000517:prevention & control; D004562:Electrocardiography / Q000187:drug effects; D020022:Genetic Predisposition to Disease; D006801:Humans; D008564:Membrane Potentials / Q000187:drug effects / Q000235:genetics; D011110:Polymorphism, Genetic; D011379:Prognosis; D011943:Receptors, Adrenergic, beta / Q000235:genetics* / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects / Q000235:genetics
chemical_list: D058666:Adrenergic beta-2 Receptor Agonists; D054316:Biomarkers, Pharmacological; D011943:Receptors, Adrenergic, beta